Qing Zhu

Qing Zhu's Title

Qing Zhu serves as the Head of China R&D, a pivotal role that underscores her extensive expertise and leadership in the field of biomedical research and development. As Head of China R&D, she is responsible for steering innovative research initiatives, overseeing the development of new therapeutic solutions, and ensuring the strategic alignment of R&D activities with the organization's global objectives. This role places her at the forefront of scientific advancements and positions her as a key influencer in the pharmaceutical industry, particularly within the Chinese market.

Qing Zhu's Education and Expertise

Qing Zhu earned her Ph.D. in molecular and cell biology from the University of Maryland, where she developed a deep understanding of complex biological systems and advanced research methodologies. Further honing her expertise, she completed post-doctoral training in the virology program at Fox Chase Cancer Center, where she specialized in viral pathogenesis and therapeutic interventions. Her educational background equips her with a robust foundation in molecular biology, virology, and biotherapeutics, making her a well-respected authority in these fields.

Qing Zhu's Experience

Qing Zhu has a distinguished career in the biotechnology and pharmaceutical industries, with significant tenures at MedImmune and Chiron Corporation (later Novartis Vaccines and Diagnostics). At MedImmune, she spent a decade focusing on antiviral biologics and novel biotherapeutics, ultimately serving as the Director of Infectious Diseases and Vaccines. Her role involved leading cross-functional teams to advance antibody candidates from preclinical stages to clinical trials, and contributing to regulatory submissions for antibody drugs targeting respiratory syncytia virus and influenza. At Chiron, she developed vaccines and a small molecular inhibitor against the hepatitis C virus, demonstrating her versatility and commitment to combating infectious diseases.

Qing Zhu's Achievements

Throughout her career, Qing Zhu has achieved significant milestones in the field of infectious disease research and biotherapeutics. At MedImmune, she played a crucial role in the regulatory submissions (IND/BLA) for several antibody drugs targeting respiratory pathogens, showcasing her ability to navigate complex regulatory landscapes and drive successful drug development programs. Her work on antiviral biologics and biotherapeutics has contributed to advancements in treatments for respiratory syncytia virus and influenza. Additionally, her efforts at Chiron Corporation in developing hepatitis C virus vaccines and inhibitors have had a lasting impact on the field of virology and infectious disease control.

Qing Zhu's Background

Qing Zhu's professional journey is marked by a series of progressive roles in leading biotech and pharmaceutical companies. At Chiron Corporation, which later became part of Novartis Vaccines and Diagnostics, she gained valuable experience in vaccine development and antiviral drug research. This was followed by a decade of impactful work at MedImmune, where she advanced to the role of Director of Infectious Diseases and Vaccines. Her background is characterized by a strong focus on antiviral biologics, novel biotherapeutics, and the development of vaccines, making her a prominent figure in the fight against infectious diseases.